Editas Joins Biotechs Braving Sluggish IPO Market
Venture capital-backed genome editing company Editas Medicine Inc. set terms Monday on a $100 million initial public offering, the fourth biotech to do so since the recent JPMorgan Healthcare Conference, amid...To view the full article, register now.
Already a subscriber? Click here to view full article